8-K: Caris Life Sciences Reports Strong 2025, Projects $1B Revenue in 2026

Caris Life Sciences announced robust financial results for Q4 and full year 2025, driven by significant growth in molecular profiling services, and provided an optimistic 2026 revenue outlook of $1.0 billion to $1.02 billion.

Summary

• Total revenue for Q4 2025 was $292.9 million, a 125% increase over the corresponding prior year period.
• Total revenue for the full year 2025 reached $812.0 million, marking a 97% increase over the full year 2024.
• The company reported net income of $82.0 million for Q4 2025, a significant improvement from a net loss of $36.9 million in Q4 2024.
• For the full year 2025, the net loss narrowed to $68.1 million, compared to a net loss of $281.9 million in 2024.
• Adjusted EBITDA was positive at $106.1 million for Q4 2025 and $137.7 million for the full year 2025, a substantial turnaround from negative figures in the prior year.
• Clinical therapy selection cases increased by approximately 20% in Q4 2025 to 52,700 cases, and by 22% for the full year 2025 to 199,300 cases.
• Gross margin improved to 75% in Q4 2025 (up 2,000 bps) and 66% for the full year 2025 (up 2,300 bps).
• Caris Life Sciences expects full year 2026 revenue to be in the range of $1.0 billion to $1.02 billion, representing 23% to 26% growth.
• The company completed the interim readout of Achieve 1, its study supporting the upcoming launch of Caris Detect, a multi-cancer early detection (MCED) test, planned for the first half of 2026.
• Strategic partnerships were announced with Everlywell for Caris Detect and with Genentech to discover novel therapeutic targets in cancers.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a highly positive report, demonstrating strong financial performance, significant operational improvements, and clear strategic direction with the upcoming Caris Detect launch and robust 2026 guidance.

Positives

• Achieved robust total revenue growth of 125% in Q4 2025 ($292.9 million) and 97% for the full year 2025 ($812.0 million).
• Transitioned to a net income of $82.0 million in Q4 2025, a significant improvement from a net loss of $36.9 million in Q4 2024.
• Reduced the full year net loss substantially to $68.1 million in 2025 from $281.9 million in 2024.
• Reported positive Adjusted EBITDA of $106.1 million in Q4 2025 and $137.7 million for the full year 2025, indicating strong operational profitability.
• Generated positive net cash from operating activities of $44.8 million in Q4 2025 and $83.2 million for the full year 2025.
• Achieved positive free cash flow of $39.7 million in Q4 2025 and $66.9 million for the full year 2025.
• Demonstrated significant gross margin improvement to 75% in Q4 2025 (2,000 bps increase) and 66% for the full year 2025 (2,300 bps increase).
• Experienced strong volume growth in clinical therapy selection cases, up 20% in Q4 2025 and 22% for the full year 2025.
• Provided an optimistic 2026 revenue outlook of $1.0 billion to $1.02 billion, projecting continued strong growth.
• The planned launch of Caris Detect, a multi-cancer early detection (MCED) test, in H1 2026 represents a significant future growth opportunity.
• Formed strategic partnerships with Everlywell for Caris Detect and Genentech for novel therapeutic target discovery.

Negatives

• Despite significant improvement, the company still reported a net loss of $68.1 million for the full year 2025.
• Pharma & research revenue decreased to $10.8 million in Q4 2025 from $35.5 million in Q4 2024, and to $45.3 million in FY 2025 from $63.1 million in FY 2024.
• Operating expenses increased by 23% in Q4 2025 and 13% in FY 2025, primarily driven by increased stock-based compensation and headcount-related costs.

Risks

• Developments in the precision medicine industry could impact future performance.
• Future financial performance, results of operations, or other operational metrics may differ from expectations.
• The development, analytical and clinical validation, timing, and performance of future solutions by Caris and its competitors pose uncertainties.
• Commercial market acceptance for solutions, including preventive and diagnostic testing paradigms, and the ability to meet resulting demand, are critical.
• The rapidly evolving competitive environment in which the company operates presents ongoing challenges.
• Third-party payer reimbursement and coverage decisions related to solutions could affect revenue.
• Risks are associated with data management, storage, and processing capabilities, and the ability to integrate and deploy artificial intelligence and advanced data analytics technologies.
• The ability to protect and enhance intellectual property is crucial for sustained competitive advantage.
• Regulatory requirements, decisions, or approvals (including their timing and conditions) related to solutions could impact market entry and operations.
• Reliance on third-party suppliers introduces supply chain risks.
• Risks related to data security, patient privacy, compliance with healthcare data protection regulations, and potential cybersecurity threats to data platforms exist.
• Compliance with various laws and regulations is an ongoing requirement.
• The outcome of government investigations and litigation could have adverse effects.
• Risks related to the company's indebtedness could impact financial flexibility.
• The ability to hire and retain key personnel is essential for continued growth and innovation.

Future Outlook

Caris Life Sciences expects full year 2026 revenue to be between $1.0 billion and $1.02 billion, representing 23% to 26% growth compared to full year 2025. Clinical therapy selection volume is projected to grow approximately 20%. Molecular profiling revenue is anticipated to grow 21% to 22% year over year, or 26% to 28% excluding out-of-year revenue from over collections recorded in 2025. Pharma & research revenue is expected to be in the range of $75 million to $85 million. GAAP operating expenses are forecast to be $590 million to $595 million, a 19% to 20% increase due to commercial expansion and pipeline trial activities, and the company expects to remain positive on Free Cash Flow and Adjusted EBITDA.

Management Comments

• "Demand for our platform continued to accelerate in 2025, driving strong growth in volume and revenue and expanding adoption across our solutions."
• "We are focused on building on this momentum, advancing our pipeline, and are particularly excited about the planned launch of our Caris Detect solution in the first half of 2026, which we believe represents a significant growth opportunity for Caris and an important step forward for precision medicine."

Industry Context

StockSavvy.ai notes that Caris Life Sciences' strong performance in molecular profiling and its planned launch of Caris Detect align with the broader trend of increasing demand for precision medicine and early cancer detection solutions. The partnerships with Everlywell and Genentech demonstrate strategic moves to expand market reach and accelerate therapeutic discovery in a highly competitive and rapidly evolving AI TechBio and diagnostics sector.

Comparison to Industry Standards

• Caris's 97% full-year revenue growth in 2025 significantly outpaces many established diagnostic and biotech companies, indicating strong market penetration and demand for its advanced molecular profiling services. For example, Foundation Medicine (a Roche company) and Guardant Health, while leaders in precision oncology, typically report lower percentage growth rates on a larger base.
• The improvement in gross margin to 66% for FY 2025 and 75% for Q4 2025 suggests strong operational efficiency and pricing power, which is competitive within the high-complexity molecular diagnostics space.
• The planned launch of Caris Detect, a multi-cancer early detection (MCED) test, positions Caris to compete in an emerging market alongside companies like Guardant Health (Shield), Exact Sciences (Cologuard, Oncoguard Liver), and Grail (Galleri), which are also developing or commercializing MCED solutions. Caris's comprehensive molecular profiling (Whole Genome, Whole Exome, Whole Transcriptome Sequencing) could offer a differentiated approach compared to competitors focusing on specific biomarkers or methylation patterns.

Stakeholder Impact

• Shareholders: Positive financial results, strong growth outlook, and strategic advancements (Caris Detect, partnerships) are likely to increase shareholder confidence and potentially share value.
• Employees: Increased headcount-related costs suggest continued investment in the workforce, potentially indicating job stability and growth opportunities.
• Customers (Patients/Physicians): Expanded adoption of solutions and the upcoming Caris Detect launch offer more advanced precision medicine options for therapy selection and early cancer detection.
• Partners (Everlywell, Genentech): Collaborations indicate active engagement and potential for mutual growth and innovation.

Next Steps

• Launch of Caris Detect multi-cancer early detection (MCED) test in the first half of 2026.
• Continue building momentum and advancing the pipeline.
• Host a conference call on February 26, 2026, at 3:30 p.m. CT (4:30 p.m. ET) to discuss financial results.
• File the Annual Report on Form 10-K on or about March 3, 2026.

Key Dates

Recommendation

The company demonstrated exceptional financial performance in 2025 with massive revenue growth, a significant reduction in net loss, and a shift to positive Adjusted EBITDA and free cash flow. The 2026 guidance projects continued strong revenue growth and profitability, driven by accelerating demand for molecular profiling services and the highly anticipated launch of the Caris Detect MCED test. These factors, combined with strategic partnerships and a strong balance sheet (high cash, low current debt), indicate robust operational health and significant future growth potential in the precision medicine market.

Keywords

precision medicine, AI TechBio, molecular profiling, cancer detection, Caris Detect, financial results, revenue growth, EBITDA, diagnostics, genomics, oncology, therapy selection, SEC filing